Market news

IQVIA's (IQV) Commercial Solutions segment is expected to see a "meaningful" tailwind from 20 novel

IQVIA Holdings (IQV) has an average rating of overweight and mean price target of $286.65, according

IQVIA Holdings (IQV) has just priced a US$2b senior notes offering due 2034, a sizable refinancing move that reshapes its debt stack and gives investors fresh information on the company’s funding costs and capital structure. Over the past year IQVIA Holdings has delivered a 42.3% total shareholder return, with the share price up 58.8% over the last 90 days and 6.9% over the past month. The recent 1.1% daily pullback to US$266.42 therefore looks more like a pause after strong momentum than a...

IQV's accelerating organic growth, robust R&DS bookings and expanding AI adoption are strengthening demand visibility and business momentum.

IQVIA Holdings (IQV) has an average rating of overweight and mean price target of $276.76, according

Broyhill Asset Management, a Charlotte-based firm, issued its second-quarter 2026 investor letter, which is available for download here. The Broyhill Equity Composite gained 8.8% in Q2, trailing the MSCI All Country World Index’s 15.1% and the MSCI ACWI Value Index’s 10.8%. For the first half, the Composite returned 2.3%, versus 11.5% for the Index. The […]

Tipranks Press Release.

The past six months have been a windfall for IQVIA’s shareholders. The company’s stock price has jumped 50%, hitting $267.77 per share. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.

RESEARCH TRIANGLE PARK, N.C., September 03, 2026--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, today announced IQVIA Predictive Clinical Development, an AI-powered approach designed to help life sciences sponsors reduce avoidable delays and bring new therapies to patients up to two years faster.

IQVIA Holdings (IQV) has an average rating of overweight and mean price target of $276.76, according

As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the drug development inputs & services industry, including IQVIA (NYSE:IQV) and its peers.

Earlier in the current quarter, IQVIA Holdings reported second-quarter results that topped earnings expectations, with adjusted earnings rising 12.1% year over year and revenue increasing 8.7%, prompting management to raise its 2026 revenue, adjusted EBITDA and adjusted diluted earnings guidance. This upgrade was backed by broad-based demand, strong bookings and contributions from acquisitions, all of which reinforced management’s view that business momentum can be sustained into 2027. With...

RESEARCH TRIANGLE PARK, N.C., August 27, 2026--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today announced it received recognition this year from multiple independent industry awards programs for its use of AI to help healthcare and life sciences organizations improve decisions, strengthen regulated workflows, protect patient privacy and optimize clinical trial execution

IQVIA (IQV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

IQV shares rise 21.7% in a month as data assets, AI-enabled technology and strong cash flow support growth despite liquidity and pricing risks.

Despite already outperforming the broader market over the past year, IQVIA continues to enjoy strong backing from Wall Street, with analysts remaining highly optimistic about the stock’s future prospects.

RESEARCH TRIANGLE PARK, N.C., August 20, 2026--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today announced that its AI-enabled Clinical Decision Support Tool, developed in collaboration with Breakthrough T1D, has won the 2026 AI Breakthrough Award for Predictive Modeling Solution of the Year.

RESEARCH TRIANGLE PARK, N.C., August 17, 2026--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today announced that it has been ranked No. 1 in Everest Group’s "Top 50™ Pharmaceutical Technology Providers" report for 2026.